Sorry, you need to enable JavaScript to visit this website.

Mechanism of Action | YONDELIS® (trabectedin) | HCP

YONDELIS® Mechanism of Action

YONDELIS® Mechanism of Action


YONDELIS® is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.1


YONDELIS® is the only treatment approved specifically for unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracycline-containing regimen1-3


Established in 6 open-label, single-arm trials, and 1 open-label, randomized, active-controlled clinical trial1


Find information about ordering YONDELIS® from specialty distributors

Treatment Considerations

Considerations for treating unresectable or metastatic liposarcoma and leiomyosarcoma, 2 of the most common subtypes of soft tissue sarcoma4



  1. YONDELIS® (trabectedin) [Prescribing Information]. Horsham, PA; Janssen Products, LP.
  2. HALAVEN® (eribulin) [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2016.
  3. VOTRIENT® (pazopanib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.
  4. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CDM, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–2930.